PEGS Summit Korea
PEGS Korea


Cancer Immunotherapy

September 21-22

The recent clinical success and regulatory approvals of anti-CTLA-4 and anti-PD-1/anti-PDL1 agents have generated an unprecedented wave of interest in immune checkpoint inhibitors (ICIs). Many believe we are only at the tip of the iceberg in realizing the full potential of immuno-oncology, whether as monotherapy or in combination with other T-cell directed agents, co-stimulatory factors or traditional therapies like radiation and chemotherapy.

Knowing Korea scientists’ strong interest in this field among its burgeoning biotech companies, CHI is pleased to introduce our Cancer Immunotherapy conference, as part of the 2nd Annual PEGS Korea. We invite international and domestic companies to share their current development and future outlook for immune checkpoint inhibitors, their challenges in the engineering and manufacturing of adoptive T-cell therapies, as well as the latest strategies and clinical updates on antibodies and bispecifics in cancer and inflammation.

Final Agenda

Download Brochure | Speaker Bios


1:00 pm Registration

1:50 Chairperson’s Opening Remarks

Jonas Schaefer, Ph.D., Head, High-Throughput Binder Selection Facility, Department of Biochemistry, University of Zurich


Philip Gotwals2:00 Treating Cancer by Targeted Activation of the Immune System

Philip Gotwals, Ph.D., Executive Director, Exploratory Immuno-Oncology, Novartis Institutes of Biomedical Research

Recent advances in immuno-oncology have the potential to transform the practice of medical oncology. Antibodies directed against negative regulators of T cell function (checkpoint inhibitors), engineered cell therapies, and innate immune stimulators such as oncolytic viruses are effective in a wide range of cancers. This presentation will illustrate therapeutic approaches to treating cancer with immune-based therapies using examples from the Novartis Immuno-oncology pipeline.

Patrick_Bauerle2:45 T Cell-Engaging Antibodies for Cancer Therapy: Modes of Action

Patrick A. Baeuerle, Ph.D., Managing Director, MPM Capital

CD19/CD3-bispecific antibody blinatumomab (Blincyto®) is approved in the US and EU for treatment of patients with relapsed/refractory B-ALL. Much still has to be learned on how such T cell-engaging antibodies can redirect any kind of T cell for target cell lysis. My presentation will cover all necessary steps including bispecific binding, T cell activation, serial lysis, T cell expansion, tumor eradication, bystander effect, epitope spreading and the impact of immune escape mechanisms.

3:30 Refreshment Break in the Exhibit Hall with Poster Viewing


4:10 Overcoming Checkpoint Blockade Resistance by TNFSF Member LIGHT

Jieyi Wang, Ph.D., CEO, Lyvgen Biopharma

Checkpoint blockade therapies with anti-PD-1/PD-L1 antibodies induce durable responses in cancer patients but fail to work in the majority of patients. Sufficient T cell infiltration in tumor tissues is a prerequisite for the response to checkpoint blockade, and targeting cancer with tumor necrosis factor superfamily member LIGHT leads to the production of chemokines that recruit massive numbers of T cells. Thus LIGHT can create a T cell-inflamed microenvironment and overcome tumor resistance to checkpoint blockade.

4:40 Bridging the Gap between Animal Models and Clinical Trials: The Use of i n vitro Assays to Accelerate Cancer Immunotherapy Development

Sofie_PattignSofie Pattijn, CTO, ImmunXperts

With the new wave of candidate cancer therapies acting mainly on the immune system via immune checkpoint blockade and other pathways, the demand for in vitro characterization of these molecules has significantly increased. This presentation will give a technical overview of a series of in vitro assays using human primary cells used for the characterization of new leads. Also, the major benefits, limitations and challenges will be discussed.

5:10 Immune Checkpoint Inhibitors: Monitoring Toxicities and Adverse Events

Amer_AlghabbanAmer Alghabban, MSc Pharmacol., Vice President, GxP Quality Assurance, Compliance and Training, Research & Development, Karyopharm Therapeutics, Inc.

The presentation aims to answer the question of why the need for monitoring toxicities/adverse events? What are the unique mechanisms and unique side effects? What are immune-related adverse events (irAEs)? How to manage immune-related adverse events (irAEs)?

5:40 Close of Day

5:40 Short Course Registration

6:00 Dinner Short Course*: Engineering of Antibody Constructs

*Separate registration required.



8:00 am Morning Coffee

8:30 Chairperson’s Remarks

Jin-San Yoo, Ph.D., CEO, President and Founder, PharmAbcine


8:40 Cancer Immunotherapy – Delivering the Promise

Weikang_Tao2Weikang Tao, Ph.D., Vice President & CEO, R&D Center, Jiangsu Hengrui Medicine Co., Ltd.

Recent breakthroughs in treating different types of advanced-stage malignancies by harnessing self-immunity against neoplastic cells showed a great promise of immunotherapy for cancer treatment. Various strategies have been employed to unleash, enhance or elicit anticancer immune reactions, which include T-cell checkpoint blockade, engineered T cells, BiTE, modified cytokines and cancer vaccines. This presentation will review recent progress in cancer immunotherapy and discuss some immunotherapeutic agents discovered and developed at Hengrui Medicine.

9:10 Anti-Cancer NK Cell Therapy Based on HSC Differentiation

Inpyo_ChoiInpyo Choi, Ph.D., Director, Immunotherapy Convergence Center, Korea Research Institute of Bioscience & Biotechnology

We have developed the efficient methods to expand and differentiate mature NK cells in vitro. Using these mature NK cells differentiated from HSC, anti-tumor activity for in vivo tumor models was tested. In vivo tests showed that mature NK cells eradicated tumors efficiently. In clinical trials, NK cells given after haploidentical HCT decreased relapse of leukemia and enhanced donor cell engraftment, but did not cause GVHD.

9:40 Novel Universal CAR-T System for Solid Tumor

Bong-Kook_KoBong-Kook Ko, Ph.D., Deputy Director, Antibody Therapeutic Research Center, AbClon, Inc.

We have developed a novel universal CAR-T system to improve safety and manufacturing process with anti-hapten CAR-T and hapten-conjugated targeting agent. The hapten is physiologically absent, pharmacologically inert and non-toxic, and high affinity anti-hapten antibody enables CAR-T cell to kill cancer cells efficiently. This system provides several advantages like micro-dosing approach, removal of CAR-T with hapten-conjugated toxin, multiple targeting with different hapten-conjugated agents, and simple manufacturing of CAR-T.

10:10 Coffee Break in the Exhibit Hall with Poster Viewing

10:40 Engineering of Anti-PDL1 Antibody-Based Bispecific/Bifunctional Antibodies for Enhanced Immunologic Activities

Zhenping_ZhuZhenping Zhu, M.D., Ph.D., Executive Vice President, Global Biologics R&D, Kadmon Corporation, LLC

11:10 MOGAM’s Bispecific Antibodies Engaging T-Cells for Cancer Therapy

Hyung-Kwon_LimHyung-Kwon (Harry) Lim, Ph.D., Senior Research Scientist, Mogam Institute for Biomedical Research

This presentation describes the challenges and opportunities of recent work of Mogam for the bispecific antibodies. The design concept of the bispecific antibodies engaging between T cells and tumor associated antigens and its characterization will be shared in terms of manufacturability and functionality. In addition, the performance about cell killing activities and T cell activation against several antigen specific cancer cells in the various experimental settings will be demonstrated.

11:40 CD19-Targeted CAR-Expressing T-Cell Therapy for B-Cell Lymphoma

Keiya Ozawa, M.D., Ph.D., Professor, Division of Genetic Therapeutics, The Institute of Medical Science, The University of Tokyo

Adoptive T-cell therapy with CD19-specific chimeric antigen receptors (CARs) has been reported to be surprisingly effective against relapsed/refractory B-cell malignancies. The ability of CD19-CAR T-cells to hone in on tumor lesions is pivotal for their ant-tumor effects, and therefore may enhance the efficacy of adoptive T-cell therapy for refractory B-cell lymphoma. The advantages of the immobilized RetroNectin and anti-CD3 antibody method for gene-modified T-cell preparation will also be presented.

12:10 Networking Luncheon in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)


1:30 Chairperson’s Remarks

Young Woo Park, Ph.D., CEO, Y Biologics

1:35 Next Generation Biologics Development Using Novel Bispecific Antibody Technologies

Chengbin WuChengbin Wu, Ph.D., CEO, EpimAb Biotherapeutics

Targeting multiple disease pathways or mediators becomes an important therapeutic strategy in a number of indications, such as inflammation and cancer. Here we present a novel bispecific technology that can efficiently combine the functions of two mAbs into one bi-functional Ig-like molecule.

2:05 Clinical Development of Tanibirumab and the Progress of Next-Generation Bispecific Antibodies

Jin-San Yoo, Ph.D., CEO, President and Founder, PharmAbcine

Tanibirumab is an anti-human VEGFR2 (KDR) neutralizing fully human IgG1 with murine/monkey cross species cross neutralizing reactivity so that all kinds of in vivo studies are possible. Tanibirumab Phase I data has shown that 60% of patients showed stable disease due to Tanibirumab and no common side effects like hypertension and hemorrhage/bleeding. Currently, Tanibirumab is in Phase IIa with recurrent GBM multi-center trial in Australia. PMC-001, a bispecific antibody neutralizing both VEGF-VEGFR2 and ANG-TIE2 pathways, is in development like PMC-201, neutralizing both VEGF-VEGFR2 and Notch-DLL4 pathways.

2:35 Next Generation Antibody Therapeutics Using Bispecific Antibody Technology

Tomoyuki Igawa, Ph.D., Department Manager, Biologics Discovery, Research Division, Chugai Pharmaceutical Co., Ltd.

We have established a bispecific antibody technology named ART-Ig to enable large scale manufacturing of the bispecific antibody. In this session, three examples of next generation bispecific antibody therapeutics will be presented: bispecific antibody against factor IXa and factor X for the treatment of hemophilia A, bispecific antibody against tumor specific antigen and T cell surface marker CD3 for cancer immunotherapy, and biparatopic antibody with pH-dependent binding property for elimination of soluble antigen from plasma.

3:05 Y Biologics’ Immunotherapeutics Programs: Development and Progress

Young Woo Park, Ph.D., CEO, Y Biologics

Y Biologics is a leading RND company with excellency in platform technologies, such as human antibody library screening, human receptor library screening and antibody optimization. Based on expertise, Y Biologics is developing first-in-class antibody drugs and bi-specific antibodies in auto-inflammatory and immune-oncology area. New cancer targeting antibody and unique immune check point antibodies, which are in early research stage, will be introduced.

3:35 Oncolytic Virus Immunotherapy Pexa-Vec and Its Place in the Immuno-Oncology Combination Regimens

HyukChan_KwonHyuk Chan Kwon, MD, Ph.D., Deputy Chief, SillaJen, Inc.

Pexa-Vec (pexastimogene devacirpvec; JX-594) has emerged as an attractive tool in oncolytic virotherapy. Apart from the direct oncolytic activity, Pexa-Vec mediates tumor cell death via the induction of innate and adaptive immune responses. In phase 1 and 2, Pexa-Vec showed cancer specific replication and objective tumor responses after intratumoral injections. It also can be replicates and express transgene products in cancer tissue after intravenous injection. Recently, we did pre-clinical studies demonstrating superior therapeutic efficacy of combining Pexa-Vec with checkpoint inhibitors compared to monotherapies. These results provide compelling evidence that Pexa-Vec can be potentiated by coupling with Immuno-Oncology drugs.

4:05 Close of Conference

Download Brochure | Speaker Bios

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Register Now

Arrow Right ColDownload 2016 Brochure

2016 PEGS Korea Brochure


Arrow Right ColCorporate Sponsor


Arrow Right ColCorporate Support Sponsors




 Thermo Fisher Scientific

Arrow Right ColSponsoring Organizations

Antibody Society Korea

Arrow Right ColView All Media Partners


Track 1
Protein & Antibody Engineering

Track 2
Cancer Immunotherapy